Hepion pharmaceuticals Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Contact Us – Hepion Pharmaceuticals

6 hours ago Hepionpharma.com

(732) 902-4000399 Thornall Street, 1st Floor Edison, NJ 08837 Phone: (732) 902-4000 Fax: (732) 902-4100 [email protected]

Website: https://hepionpharma.com/contact-us/

Category: Phone Number, Contact SupportShow Details ››

Hepion Pharmaceuticals Crunchbase Company Profile & Funding

5 hours ago Crunchbase.com

(732) 902-4000Phone Number (732) 902-4000 Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).

Founded: 2013

Website: https://www.crunchbase.com/organization/contravir-pharmaceuticals

Category: Phone NumberShow Details ››

Hepion Pharmaceuticals Company Profile Office Locations

2 hours ago Craft.co

Hepion Pharmaceuticals has 588 Twitter Followers. The number of followers has increased 3.5% month over month and increased 75.2% quarter over quarter

Website: https://craft.co/contravir-pharmaceuticals

Category: Contact NumberShow Details ››

Pipeline – Hepion Pharmaceuticals

4 hours ago Hepionpharma.com

Hit enter to search or ESC to close. About. Company Overview; Executive Team; Cyclophilin Expertise; Board of Directors

Website: https://hepionpharma.com/pipeline/

Category: Contact NumberShow Details ››

Hepion Pharmaceuticals, Inc. 10K Mar. 31, 2021 4:57 PM

9 hours ago Seekingalpha.com

Hepion Pharmaceuticals, Inc. (HEPA) FORM 10-K Commission File Number 001-36856. Click to enlarge HEPION PHARMACEUTICALS, INC. and contact information, is required to be sent to the

Website: https://seekingalpha.com/filing/5458356

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals : to Present on CRV431 and AIPOWR

4 hours ago Marketscreener.com

Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission. Contact: Stephen Kilmer. Tel: (646

Website: https://www.marketscreener.com/quote/stock/HEPION-PHARMACEUTICALS-I-63216091/news/Hepion-Pharmaceuticals-to-Present-on-CRV431-and-AI-POWR-at-NASH-TAG-2021-32671921/

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals Announces Postponement of 2021

3 hours ago Stocktitan.net

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Website: https://www.stocktitan.net/news/HEPA/hepion-pharmaceuticals-announces-postponement-of-2021-annual-meeting-pasdh7s6yglk.html

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals Inc Company Profile and News

9 hours ago Bloomberg.com

Company profile page for Hepion Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information

Website: https://www.bloomberg.com/profile/company/HEPA:US

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals, Inc. (HEPA) Company Profile

4 hours ago Finance.yahoo.com

See the company profile for Hepion Pharmaceuticals, Inc. (HEPA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key …

Website: https://finance.yahoo.com/quote/HEPA/profile

Category: Contact NumberShow Details ››

Hepion Pharmaceuticals : DEF 14A MarketScreener

2 hours ago Marketscreener.com

To Be Held on June 25, 2021 Dear Stockholder: We are pleased to invite you to attend the annual meeting of stockholders (the "Annual Meeting") of Hepion Pharmaceuticals, Inc. ("Hepion" or the "Company"), which will be held on June 25, 2021 at 9:00 a.m. local time at our offices, located at 399 Thornall Street, First Floor, Edison, NJ 08837, for the following purposes:

Website: https://www.marketscreener.com/quote/stock/HEPION-PHARMACEUTICALS-I-63216091/news/Hepion-Pharmaceuticals-DEF-14A-33235468/

Category: Contact NumberShow Details ››

Hepion Pharmaceuticals : Announces Adjournment of Annual

3 hours ago Marketscreener.com

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580

Website: https://www.marketscreener.com/quote/stock/HEPION-PHARMACEUTICALS-I-63216091/news/Hepion-Pharmaceuticals-Announces-Adjournment-of-Annual-Meeting-Form-8-K-35733916/

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals : Announces Postponement of 2021

5 hours ago Marketscreener.com

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580

Website: https://www.marketscreener.com/quote/stock/HEPION-PHARMACEUTICALS-I-63216091/news/Hepion-Pharmaceuticals-Announces-Postponement-of-2021-Annual-Meeting-of-Stockholders-Form-8-K-35941871/

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals Announces Pricing of Public

1 hours ago Globenewswire.com

About Hepion Pharmaceuticals. The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. There are a number

Website: https://www.globenewswire.com/news-release/2021/02/16/2175893/0/en/Hepion-Pharmaceuticals-Announces-Pricing-of-Public-Offering.html

Category: Contact NumberShow Details ››

Hepion Pharmaceuticals, Inc WTEXP 070323 (CTRVW) Stock

3 hours ago Investorshub.advfn.com

Hepion Pharmaceuticals, Inc: The aggregate number of shares of Common Stock to be issued pursuant to the Class A Units and issuable upon conversion of all the Series E Convertible Preferred Stock is 2,600,000. The aggregate number of Warrants to be issued in the offering is 2,600,000. please contact: Stephen Kilmer ContraVir Investor

Website: https://investorshub.advfn.com/HEPION-PHARMACEUTICALS-INC-WTEXP-070323-CTRVW-37373/

Category: Contact SupportShow Details ››

HEPION PHARMACEUTICALS : ANNOUNCES POSITIVE TOPLINE …

7 hours ago Marketscreener.com

Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. Contact: Stephen Kilmer

Website: https://www.marketscreener.com/quote/stock/HEPION-PHARMACEUTICALS-I-63216091/news/HEPION-PHARMACEUTICALS-ANNOUNCES-POSITIVE-TOPLINE-DATA-FROM-PHASE-2A-AMBITION-NASH-TRIAL-ALL-PR-35859801/

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals Announces Adjournment of Annual

5 hours ago Leagold.ceo.ca

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2020 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Website: https://leagold.ceo.ca/@nasdaq/hepion-pharmaceuticals-announces-adjournment-of-annual

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals (HEPA) Coverage Starts at $4.50

4 hours ago Choresearch.com

Stock: Hepion Pharmaceuticals (HEPA) Stock Rating: CONVICTION BUY. Price Target: $4.50 (187% Upside)Market Price: $1.57. Research Publication Date: 5/24/2021. Hepion Pharmaceuticals (HEPA), is a biopharmaceutical company, whose main focus is on the development of treatments for liver disease which are caused by nonalcoholic steatohepatitis (NASH) and also …

Website: https://www.choresearch.com/2021/05/24/hepion-pharamceuticals-hepa-coverage-starts-at-4-50-price-target/

Category: Contact NumberShow Details ››

Hepion Pharmaceuticals Announces Positive Topline Data

8 hours ago In.finance.yahoo.com

EDISON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the

Website: https://in.finance.yahoo.com/news/hepion-pharmaceuticals-announces-positive-topline-120000659.html

Category: Contact NumberShow Details ››

Hepion Pharmaceuticals Prices Public Offering – Business

6 hours ago Ipsnews.net

(646) 274-3580Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission. For further information, please contact: Stephen Kilmer Hepion Pharmaceuticals Investor Relations Direct: (646) 274-3580 [email protected]

Website: https://ipsnews.net/business/2020/11/25/hepion-pharmaceuticals-prices-public-offering/

Category: Contact SupportShow Details ››

Hepion Pharmaceuticals Announces Postponement of 2021

4 hours ago Forextv.com

About Hepion Pharmaceuticals. The Company’s lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. There are a number

Website: https://forextv.com/top-news/hepion-pharmaceuticals-announces-postponement-of-2021-annual-meeting-of-stockholders/

Category: Contact NumberShow Details ››

Hepion Pharmaceuticals Inc. (HEPA): The stock’s

8 hours ago Baxterreport.com

The total number of common shares currently owned by the public is 76.23 million. HEPA does have institutional investors; and they hold 24.10% of the stock. Hepion Pharmaceuticals Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Website: https://baxterreport.com/2021/07/30/hepion-pharmaceuticals-inc-hepa-the-stocks-intermediate-term-indicators-point-to-sell-today/

Category: Contact NumberShow Details ››

Please leave your comments here:

Popular Brands

Hms
Htsc
H M